Sandra Horning, MD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of atezolizumab (Tecentriq) in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (SCLC).1
Immune-related adverse events (irAEs) were more common with atezolizumab compared with placebo (39.9% vs 24.5%). The most common grade 1/2 irAEs among the atezolizumab and placebo arms included rash (16.7% vs 10.2%, respectively), hepatitis (5.6% vs 4.6%), infusion-related reactions (3.5% vs 4.6%), pneumonitis (1.5% vs 1.5%), and colitis (0.5% vs 0%).
- CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer. Roche. Published July 26, 2019. https://bit.ly/2K2A6bY. Accessed July 26, 2019.
- Liu S, Mansfield A, Szczesna S, et al. IMpower 133: primary PFS, OS and safety in a ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC. Presented at: the IASLC 19th World Conference on Lung Cancer; September 23-26, 2018; Toronto, Canada. Abstract PL02.07.
- Liu S, Mansfield A, Szczesna S, et al. First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Eng J Med. 2018;doi:10.1056/NEJMoa1809064.
... to read the full story